Pfizer (PFE) offered up some more details on its weight loss drug pipeline on Tuesday during a call with investors after it ...

Pfizer has a pill it's developing called danuglipron, which is in early-stage trials but has demonstrated that it's ...

Eli Lilly CEO David Ricks told investors this week that the sale of cheaper, knockoff versions of the company’s blockbuster ...

Rather than bribing and wheedling physicians to pretty-please-prescribe-our-drug, websites allow companies to deal drugs ...

Doubling down on the bad news, Pfizer's journey into the weight loss drug market has fallen flat, as its twice-daily obesity-fighting pill danuglipron triggered nausea and other stomach issues in ...

The U.S. Food and Drug Administration approved Pfizer's once-a-week injection for the two main types of a rare bleeding ...

Pfizer now expects between $61 billion and $64 billion in revenue for the year and raised its outlook for adjusted earnings ...

Pfizer, a multinational pharmaceutical and biotechnology corporation, is now a $159 billion (by market cap) healthcare giant.

Pfizer's anti-GDF-15 antibody ponsegromab was able to achieve weight gain ... programme for the drug next year. Cachexia is a complicated metabolic disorder that results in loss of muscle and ...

The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...

Recent health news highlights include Amgen addressing bone density concerns, AstraZeneca revising its financial outlook ...

Pfizer (PFE) offered up some more details on its weight loss drug pipeline on Tuesday during a call with investors after it posted its third-quarter earnings report. During the call, the pharma ...